Post-operative Monitoring of Gastric Cancer
- Conditions
- Gastric Cancer
- Registration Number
- NCT07026240
- Lead Sponsor
- Suzhou Huhu Health & Technology Inc.
- Brief Summary
This study is to determine the performance of non-invasive new multi-target biomarkers in the post-operative monitoring of gastric cancer.
- Detailed Description
This study aims to develop and validate a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood. Blood will also be collected at various time points post-operatively. We will determine whether these new biomarkers can be used as prognostic biomarkers to predict tumor recurrence and metastasis. We will also determine whether these new biomarkers detect tumor recurrence and metastasis earlier than methods currently used in the clinic such as imaging and tumor biomarkers CA19-9, CEA, and CA72-4.
This study is a prospective and multi-center study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 258
- Subject age over 18.
- Subject has stomach discomfort, and seek medical attention at the Gastric Surgery Department of our center.
- Subject has or will have gastroscopy and/or pathological examination results at this center.
- Subject must be able to fully understand the informed consent form and be able to personally sign it.
- Subject has serious heart, liver, kidney dysfunction, or mental illness.
- Subject diagnosed previously with any kind of malignant tumor.
- Subject is known to be infected with HIV or other related diseases (considering interference from the use of immune drugs).
- Subject is receiving targeted drugs, immunosuppressants, immunomodulators, and biological therapies.
- Researchers believe that subject is not suitable for enrollment.
- Subject can not supply sufficient sample to complete this experiment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The performance of the new biomarkers in the post-operative monitoring of gastric cancer 2 years Number of Participants With Tumor Recurrence Detected by the New System vs. Imaging and Serum Markers (CA19-9, CEA, CA72-4).
- Secondary Outcome Measures
Name Time Method Metastasis Detection Time: New vs. Conventional Methods 2 years Time to Detection of Metastasis (Days) by the New System Compared to Conventional Methods.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center🇨🇳Shanghai, Shanghai, ChinaDazhi Xu, MD., PhDContact+8615862461212jiangnan@sz-hoho.com